NY-MOODY'S-ANALYTICS
10.6.2019 08:32:06 CEST | Business Wire | Press release
Moody's Analytics has announced the launch of the Certification of Professional Competence in Mortgage Lending in Hungary, in collaboration with the Budapest Institute of Banking (BIB) and the International Training Center for Bankers (ITCB).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190609005060/en/
The certification program meets the requirements of the European
Parliament and Council Directive on Mortgage Credit. The objective of
the mandate is to ensure a minimum standard of competency and ethics
among mortgage lenders, specifically applicable to the following roles:
-
Bank professionals in the front, middle and back office engaged in
residential mortgage lending (for example, product design, underwriting,
administration and management, as well as selling)
- Mortgage
brokers who propose, offer, and/or sell residential mortgages
-
Managers of employees listed above
- Individuals aspiring to work
in any position related to the Hungarian mortgage market
Beyond meeting regulatory requirements, the program is designed to elevate the consultative skills of lending professionals and help them become responsible advisers to their customers, in line with the objectives of Hungarian banks and the evolving expectations of the market.
The program delivers a modern learning experience by using advanced technology to personalize the learning and expedite the impact while minimizing the workload for those who already possess the required skills.
Gergely Fábián, Chief Executive Officer of BIB, noted, “We are delighted to work with Moody’s Analytics and to bring their educational framework and professional knowledge in mortgage lending to Hungary. The program aims to instill best practices in lending for mortgage lenders in the Hungarian Banking industry.”
Béla Öcsi, Chief Executive Officer of the ITCB, added, “The innovative Credit Coach framework from Moody’s Analytics brings an enhanced learning experience for all participants. We are pleased to be able to deliver substantial value to the local banking sector through the collaboration with BIB and Moody’s Analytics.”
“We are honored to collaborate with the BIB and ITCB to deliver a program that represents the highest standards in international credit practices, adapted to the unique context of the Hungarian banking industry,” added Ari Lehavi, Executive Director at Moody’s Analytics. “We look forward to supporting similar institutes across the region in their goal of addressing the certification requirements of the European Mortgage Credit Directive, as applicable in their local market.”
Moody’s Analytics recently collaborated with the Hellenic Banking Institute to offer the Certification of Professional Competence in Mortgage Lending program in Greece.
Click here to learn more about Moody’s Analytics Learning Solutions, including Credit Coach.
About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter or LinkedIn .
Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 42 countries.
About the Budapest Institute of Banking
The foundation of the Budapest Institute of Banking (BIB) is rooted in the matching of market needs with the social responsibility objectives of the Magyar Nemzeti Bank (the Central Bank of Hungary) and the Budapest Stock Exchange.
A modern education centre has been created where up-to-date knowledge is transferred in the form of experience-based learning. Forms of edutainment are an integral part of the teaching methodology. Covering the entire operational range of the banking, financial, and insurance sector, the courses grant the opportunity to participants, from experts to top managers, to gain cutting-edge knowledge and to discover professional development opportunities.
The BIB aims to train experts who will be able to address the challenges of the future.
For more information please visit our website: https://www.bib-edu.hu/en .
About International Training Center for Bankers (ITCB)
Founded 30 years ago, ITCB has been providing quality financial education and specialized risk consultancy services for the banking sector in Hungary, Central and Eastern Europe and the Middle East. Building on its long track record and synergies between advisory and training, ITCB’s current offering focuses on tailor-made case study-driven banking seminars, e-learning courses and financial simulations. For more information about ITCB, visit our website .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190609005060/en/
Contact:
KATERINA SOUMILOVA Moody’s Analytics Communications +1.212.553.1177
Moody's Analytics Media Relations
moodysanalytics.com twitter.com/moodysanalytics linkedin.com/company/moodysanalytics
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
